Piper Sandler analyst David Amsellem lowered the firm’s price target on Eagle Pharmaceuticals to $31 from $41 and keeps a Neutral rating on the shares post the Q4 results. The analyst struggles with the company’s longer-term trajectory of EBITDA, given a declining contribution from bendamustine products owing to the availability of generics of the legacy form of the molecule, along with likely declining contribution from Pemfexy due to competitive realities.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EGRX:
- Eagle Pharmaceuticals sees 2023 adjusted EPS $4.20-$4.53, consensus $4.49
- Eagle Pharmaceuticals reports Q4 adjusted EPS $1.10, consensus 83c
- Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
- Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference
- Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
